The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global albumin market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Albumin is a water-soluble globular protein present in blood plasma. It is synthesized in the liver and is essential for maintaining the blood volume and transportation of enzyme, hormone and bile salt molecules. It is commonly available in human, bovine and recombinant variants. They are crucial for sustaining the intravascular colloid osmotic pressure (COP) and preventing leakage of fluids into the tissue. It is commonly used as a blood volumizer for the treatment of rare diseases, burns, liver disorders, blood loss trauma and surgical complications. It is also utilized in pharmaceutical drugs for stabilization, enhancing surface absorption and reducing aggregation and oxidation. As a result, albumin finds extensive application in the manufacturing of drug delivery systems, therapeutics, culture media and vaccines.
The increasing prevalence of chronic medical ailments across the globe is one of the key factors driving the growth of the market. Albumin is widely used in the treatment of hypovolemia, acute respiratory distress syndrome, nephrosis, renal dialysis, liver failure, cardiopulmonary disorders and hypoalbuminemia. Moreover, the rising geriatric population, which is more susceptible to such ailments is providing a thrust to the market growth. In line with this, the onset of the coronavirus (covid-19) pandemic has also resulted in the increasing utilization of albumin for the development of drugs and stable vaccine formulations. Additionally, the widespread adoption of human serum albumin (HSA) for replenishing proteins in human plasma and maintaining plasma colloid oncotic pressure is acting as another growth-inducing factor. It also aids in preventing the denaturation of active protein ingredients, thereby making it highly beneficial for the production of vaccines. Other factors, including the introduction of albumin-based nanoparticles, along with extensive research and development (R&D) activities in the field of biotechnology, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global albumin market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product, application and end user.
Breakup by Product:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Albumedix Ltd, Biotest AG, Celgene Corporation (Bristol-Myers Squibb Company), CSL Limited, Grifols SA, HiMedia Laboratories, Medxbio Pte Ltd, Merck KGaA, Octapharma AG, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc. and Ventria Bioscience Inc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Albumedix Ltd, Biotest AG, Celgene Corporation (Bristol-Myers Squibb Company), CSL Limited, Grifols SA, HiMedia Laboratories, Medxbio Pte Ltd, Merck KGaA, Octapharma AG, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc. and Ventria Bioscience Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at